Heres how it stacks up: Compared to Other GLP-1 Agonists : Semaglutide is generally more effective at reducing HbA1c and promoting weight loss compared to other drugs in its class
KFFs analysis of newly released Medicare Part D spending data from CMS shows that total gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss Ozempic, Rybelsus, and Mounjaro has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022 (Figure 1)
July 15, 2025.
Plus, you have the social component. Indeed, doubling down on interactive elements, from social interactions to unique dining experiences, can keep guests coming into restaurants, even if their appetites are curbed
They can advise you on the right dosage schedule, address GLP-1 nausea or any other side effects that come up, and help you stay motivated during titration